Firebrick Pharma's Quarterly Activity Report for March 2024

Firebrick Pharma Limited (ASX: $FRE) has released its Quarterly Activity Report for the quarter ending 31 March 2024. The company reported the launch of Nasodine Nasal Spray in the United States and the publication of Phase 2 COVID-19 trial results. Firebrick's cash and cash equivalents at the end of March 2024 were $721,000, with net cash outflows from operations for the quarter amounting to $592,000.

Executive Commentary on Recent Developments

The Company is excited to announce the successful launch of Nasodine Nasal Spray in the US market, marking a significant milestone in our efforts to provide a nasal antiseptic/disinfectant solution. The publication of our Phase 2 COVID-19 trial results in the esteemed journal, Laryngoscope, further validates the efficacy of Nasodine in reducing viral load and clearing the virus from the respiratory tract. We are also pleased to have received a second US patent related to COVID-19, extending Nasodine's protection and reinforcing its potential in reducing the risk of transmission. We remain committed to advancing our product portfolio and look forward to the future availability of our other products in the US market.

Summary of Firebrick Pharma's Quarterly Activity Report

Firebrick Pharma (ASX: $FRE) has made significant strides in the quarter ending 31 March 2024, with the launch of Nasodine Nasal Spray in the US market and the publication of positive Phase 2 COVID-19 trial results. The company's cash and cash equivalents stood at $721,000, with net cash outflows from operations amounting to $592,000. Firebrick remains optimistic about the future revenue from the sale of Nasodine internationally and anticipates lower research and development costs as it continues to preserve cash for its international plans. The company has not taken any steps to raise further capital and expects to continue its operations and meet its business objectives based on the successful launch of Nasodine and its confidence in raising further funds as needed.